Onconova full-year net loss $19.0M; cash $38.8M into Q1 2024

Traws Pharma, Inc.

Net loss $19.0M ($0.91 loss per share) vs $16.2M ($0.96 loss per share) in 2021 on higher shares outstanding.
Cash and equivalents $38.8M at Dec 31, 2022, down from $55.1M; cash runway into Q1 2024.
R&D expenses rose to $11.4M from $7.3M, driven by narazaciclib development and manufacturing.
Narazaciclib Phase 1 advancing to 240 mg continuous daily cohort; LGEEC trial opening Q1 2023, data Q4 2023.
Two complete responses in RDEB-associated SCC with rigosertib; plan to discuss regulatory path with agencies.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Traws Pharma, Inc. reported the twelve months ended December 31, 2022 results: net income $19.0 million, EPS $0.91 per share.

Period: the twelve months ended December 31, 2022
Net income: $19.0 million
EPS: $0.91 per share
Result: reported results

Exact text from the filing

Net loss for 2022 was $19.0 million, or $0.91 per share on 20.9 million weighted average shares outstanding, compared with a net loss of $16.2 million, or $0.96 per share for 2021 based on 16.8 million weighted average shares outstanding.

View on SEC.gov

Browse all earnings releases →

Traws Pharma, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-23-033367

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.